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Edited by Takashi GojoboriAbstract The P2X7 gene is important for the innate immune re-
sponse but known polymorphisms do not explain all subjects with
loss of P2X7 function. A splice site mutation (gﬁ t) was found
at position +1 of the ﬁrst intron of the P2X7 gene in 7 of 336
Caucasians and 1 of 39 subjects of Indian ethnicity. All eight
subjects were heterozygous for the uncommon 1513Aﬁ C poly-
morphism of the P2X7 gene. RT-PCR and sequencing showed
the splice site mutation was on the 1513C allele in the Cauca-
sians and on the 1513A allele in the Indian subject. The splice
site mutation is an inherited polymorphism and gives rise to a
P2X7 null allele in 1–2% of the Caucasian population.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Purinergic P2X7 receptors are cytolytic receptors which are
highly expressed on the cells of the monocyte–macrophage ser-
ies as well as lymphocytes [1] and which participate in the in-
nate immune response against intracellular mycobacteria and
Chlamydia [2–5]. This receptor, like other members of the
P2X receptor family has two transmembrane domains and
intracellular carboxyl and amino termini [6,7]. Activation of
the receptor by extracellular ATP leads to an immediate open-
ing of a cation selective channel which in the continued pres-
ence of agonist dilates within the ﬁrst minute to a pore
accepting cationic permeants up to the size of ethidium+
(314 Da) or YoPro-12+ (375 Da) [7,8]. This latter permeability
state allows accurate quantitation of receptor function by mea-
surement of the ATP-induced rate of ethidium+ inﬂux [8].
Wide variations in P2X7 function have been observed between
individuals both in normal and chronic lymphocytic leukemic
cohorts [1,9]. Genetic factors play a major role in this func-
tional variability and at least three polymorphisms within the
coding region of the P2X7 gene have been shown to abolish
receptor function [10–12]. In around 20% of the CaucasianAbbreviations: RT-PCR, reverse transcription-polymerase chain reac-
tion; SNP, single nucleotide polymorphism; PLD, phospholipase D;
mAb, monoclonal antibody
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which is located in the ankyrin repeat motif of the carboxyl ter-
minus leads to loss of function [12]. Homozygosity for this
polymorphism does not alter the amount of P2X7 protein
but abolishes pore formation while the heterozygous state
gives cells with half the pore function of cells with wild type
P2X7 protein [12]. A second polymorphism, Ile-568 to Asn
(1729 Tﬁ A) lies in a traﬃcking motif of the carboxyl termi-
nus and prevents normal traﬃcking and surface expression of
the receptor [11]. A third polymorphism, Arg-307 to un-
charged glutamine (946 Gﬁ A) lies within the ATP binding
pocket of the extracellular domain and abolishes the binding
of ATP to the receptor [10]. However, these known polymor-
phisms do not explain absence of function in all individuals.2. Materials and methods
2.1. Selection of subjects
Peripheral venous blood was collected with informed consent from
both normal subjects (n = 147) and patients (n = 189) of Caucasian
ethnicity. Patient diagnoses included chronic lymphocytic leukemia
(n = 131), lymphoma (n = 43) and various autoimmune diseases
(n = 15), the latter patients all having raised anti-nuclear antibody
titers. Consenting normal subjects of Indian or Sri Lankan ethnicity
were also studied (n = 39).
2.2. Single nucleotide polymorphism (SNP) analysis
Genomic DNA was isolated from peripheral blood using the Wizard
genomic DNA puriﬁcation kit (Promega) according to the manufac-
turers instructions. DNA samples were analysed by high throughput
TaqMane assay using a ABI Prism 7900HT sequence detection sys-
tem (Applied Biosytems) at the SUPAMAC Facility, Royal Prince
Alfred Hospital, Sydney, Australia. Mutations of the P2X7 gene were
analysed at positions 151+1 (exon 1), 946 (exon 9), 1513 and 1729
(exon 13) using the following primer and probe sets:
151+1: Forward Primer 5 0-ttcttccacgtgatcatcttttcct-3 0, Reverse Pri-
mer 5 0-cggccactgcagagatctg-30, Probe VIC 5 0-cccacttaccaaacgt-30,
Probe FAM 5 0-cccacttaacaaacgt-3 0
946: Forward Primer 5 0-cagatacgccaagtactacaaggaa-30, Reverse Pri-
mer 5 0-tcaaaacggatcccgaagacttt-3 0, Probe VIC 5 0-atgttgagaaacggactc-
3 0, Probe FAM 5 0-atgttgagaaacagactc-30
1513: Forward Primer 5 0-gctgcctcccatctcaactc-30, Reverse Primer 5 0-
gctctgaggtggtgatgca-3 0, Probe VIC 5 0-agcacagctcctccag-3 0, Probe
FAM 5 0-cacagcgcctccag-3 0
1729: Forward Primer 5 0-cttcggctcccaggacatg-30, Reverse Primer 5 0-
cctccagcggcagca-3 0, Probe VIC 5 0-ctttgccatcctgcc-3 0, Probe FAM 5 0-
tttgccaacctgcc-3 0
All samples in which amutationwas detected were sequenced conven-
tionally to verify the result [10]. Brieﬂy, samples in a reactionmix consist-
ing of 400 nM forward and reverse primers, 1.5 mM MgCl2, 100 lM
dNTPs, 0.025 U/lL Taq DNA polymerase in 1· PCR buﬀer (Invitro-
gen), were subjected to 39 rounds of PCR ampliﬁcation (denaturationblished by Elsevier B.V. All rights reserved.
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9) or 66 Cfor 15 s (exon13), extensionat 72 Cfor 15 s). ThePCRprod-
ucts were separated on a 2% agarose gel and visualized with ethidium
bromide staining to determine if fragments of the correct size had been
ampliﬁed. Ampliﬁed products were puriﬁed using the GFXe PCR
DNA and Gel Band Puriﬁcation kit (Amersham Biosciences) according
to the manufacturers instructions. Sequencing was carried out on an
ABI PRISM 377 DNA Sequencer at the SUPAMAC Facility.
2.3. RNA analysis
Freshly collected peripheral blood was diluted 3-fold with phos-
phate-buﬀered saline and mononuclear cells were isolated by density
gradient centrifugation over Ficoll-Paque (Amersham Biosciences).
Mononuclear cells were washed once with cold phosphate-buﬀered sal-
ine (4 C) and RNA was isolated from these cells using Total RNA iso-
lation reagent (ABgene) according to the manufacturers instructions.
Primers were designed to span the junction of exons 1 and 2 (left 5 0-
gtcactcggatccagagcat-30; right 5 0-ggtgtagtctgcggtgtcaa-3 0) and exons 12
and 13 ( left 5 0-ggatggtgaaccagcagcta-30; right 5 0-aagccactgtactgcccttc-
3 0) using Primer3 (www-genome.wi.mit.edu/cgi-bin/primer3_www.cgi)
and were synthesised by Sigma-Genosys. cDNA was generated and
ampliﬁed using a Superscript One-Step reverse transcription-
polymerase chain reaction (RT-PCR) with Platinum Taq kit
(Invitrogen) according to the manufacturers instructions. Reverse
transcription was performed at 55 C for 30 min followed by PCR
(35 cycles of denaturation at 95 C for 15 s, annealing at 58 C for
30 s, extension at 72 C for 1 min). Products were separated on a 2%
agarose gel and visualized by ethidium bromide staining. Ampliﬁed
products were puriﬁed and sequenced.
2.4. P2X7 function
P2X7 function was determined by measuring the ATP induced up-
take of ethidium+ by B- and T-lymphocytes and monocytes using
time-resolved ﬂow cytometry as previously described [1]. Brieﬂy,
mononuclear cells from peripheral blood were labeled with FITC-con-
jugated anti-CD monoclonal antibody (mAb). Ethidium+ (25 lM) was
added to a cell suspension maintained at 37 C with stirring in a Time
Zero module, and 40 s later 1 mM ATP was added. The cells were ana-
lysed at 1000 events/s on a FACSCalibur ﬂow cytometer and gated by
forward and side scatter and by cell type speciﬁc mAb.3. Results
During a search for new mutations in subjects with absent
P2X7 function, we studied a subject of Indian origin (SubjectTable 1
P2X7 mutational status and function of subjects heterozygous for the 151+1
Subject Details Genotype
Age Sex Race 151+1 946
1 33 M Indian G/T WT
2 69 M Cauc G/T WT
3 70 M Cauc G/T WT
4a 51 F Cauc G/T WT
5 48 M Cauc G/T WT
6 36 M Cauc G/T WT
7 67 F Cauc G/T WT
8 38 M Cauc G/T WT
Normalsb (n = 15) Cauc WT WT
Normalsc (n = 6) Cauc WT WT
Normalsd (n = 4) Cauc WT WT
ND, not determined. S.E.M., standard error of the mean.
aSubject 4 is the daughter of Subject 3.
bAverages for subjects wild type for all four loss of function positions.
cAverages for subjects heterozygous at 1513.
dAverages for subjects homozygous at 1513.1) whose DNA showed a gﬁ t substitution at position +1
at the 5 0 boundary of intron 1. Screening of DNA from 336
subjects of Caucasian background and a further 38 Indian
subjects by high throughput Taqmane Assay for this 151+1
mutation as well as other loss-of-function SNPs (946, 1513,
and 1729) identiﬁed a further seven Caucasian subjects in
addition to the one Indian subject with a heterozygous muta-
tion at the 151+1 position of the P2X7 gene (Table 1). Collec-
tively the splice site mutation was present in seven out of 336
subjects giving an overall allele frequency of 0.01 (1%) in the
Caucasian population when healthy subjects and patients are
considered as a single group. Thus this mutant allele can be
considered an uncommon polymorphism with a prevalence
equal to that (P 0.01) which deﬁnes a single nucleotide
polymorphism.
Three diﬀerent splice site prediction programs (BDPG Splice
Site Predictor, NetGene2 and SplicePredictor), predicted that
this gﬁ t substitution at the exon 1/intron 1 boundary would
disrupt the 5 0 donor splice site of intron 1. Without splicing of
intron 1, translation of mRNA could continue for 523 bases
into the intronic region before reaching a stop codon. Up-
stream of this stop codon are two alternative 5 0 donor splice
sites 273 or 516 bp downstream of exon 1. We analysed total
RNA from mononuclear cells by RT-PCR using primers de-
signed to span the boundary between exon 1 and exon 2, an
approach designed to eliminate ampliﬁcation of possible
DNA contaminants and to show if larger sized products were
present. A 2% agarose gel of the product showed only one
mRNA species to be present which was identical in size to
the product obtained from a control subject wild type at the
151+1 position (Fig. 1). Sequencing of the RT-PCR product
revealed that both the control subject and the Indian subject
were wild type across the exon 1/exon 2 boundary indicating
that the allele containing the 151+1 mutation does not produce
a splice variant of P2X7.
Unexpectedly analysis of genomic DNA showed all eight
subjects heterozygous at the 151+1(g/t) position were also het-
erozygous at position 1513(A/C) of this gene although based
on a 1513C allele frequency of 0.16 it was expected that only
one or two of the eight subjects would inherit the 1513C allelesplice site polymorphism
P2X7 function (arbitrary units)
1513 1729 B-cells T-cells Monocytes
A/C WT 145 18 8
A/C WT 753 ND 1954
A/C WT 7548 269 5553
A/C WT 1308 541 14271
A/C WT 588 192 2498
A/C WT 287 332 3410
A/C WT ND ND ND
A/C WT ND ND ND
WT WT 2506 2224 22330
(SEM) (587) (741) (2611)
A/C WT 900 404 9130
(SEM) (290) (140) (3959)
C/C WY 210 28 258
(SEM) (69) (28) (211)
Fig. 1. RT-PCR of RNA covering the exon1/exon 2 boundary. (A)
Only one species of mRNA (231 bp) was detected from subjects
heterozygous at 151+1 (only Subject 1 shown) and a normal control
(wild type at 151+1). (B) Sequencing of products conﬁrmed that the
mRNA species are identical and wild type spanning the exon1/exon 2
boundary in both 151+1 heterozygous and wild type subjects.
Fig. 2. Comparison of gDNA and cDNA from two subjects hetero-
zygous at 151+1 and 1513 and a normal subject wild type at 151+1 and
heterozygous at 1513. Subject 1 and Subject 4 are 1513 A/C at the
gDNA level but Subject 1 only expresses a 1513C allele at the mRNA
level, while Subject 4 expresses only a 1513A allele. The normal subject
expresses both A and C alleles in gDNA and at the mRNA level.
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around the 1513 position in these eight subjects. In cDNA
from Subject 1 only cytosine was found at position 1513 con-
sistent with complete degradation of mRNA from the 151+1
gﬁ t allele (Fig. 2). These data showed that in the Indian sub-
ject the 151+1 and 1513C mutation were located on separate
alleles of the P2X7 gene. Diﬀerent results were obtained for
the Caucasian subjects, three of whom were available for
study. Sequencing of cDNA showed that the expressed allele
was of genotype 1513A (Fig. 2). This result indicated that
the 151+1 gﬁ t mutation in Caucasians had occurred on the
1513C allele.
The inheritance of the 5 0 splice site polymorphic allele was
studied by genotyping the DNA from four of the children of
Subject 3. One of the children was heterozygous for this allele
typing as 151+1 g/t and 1513 A/C. The other three children
were wild type at both these positions of the P2X7 gene.
Measurement of P2X7 function in mononuclear cells of the
peripheral blood by ATP-induced uptake of ethidium bro-
mide as described previously [1] were consistent with the
splice site mutation 151+1 gﬁ t occurring on a wild type al-
lele in the Indian subject but on a 1513C allele in the Cauca-
sians. Mononuclear cells from the Indian subject showed a
complete absence of P2X7 function (Table 1). Subjects homo-
zygous for the 1513C allele have been previously shown to
have absent P2X7 function [12], therefore the presence of a
null allele together with a single 1513C allele is consistent with
the complete lack of function observed in the Indian subject.
In contrast mononuclear cells in ﬁve of the Caucasian subjects
available for study showed low to moderate P2X7 function
which was consistent with the expression in a hemizygous
state of a single 1513A (wild type) allele (Table 1). All eight
subjects were wild type at the two other polymorphic sites
in the gene (946 and 1729) known to lead to loss of receptor
function.4. Discussion
Mutations involving the splice site sequences at intron/exon
boundaries are a common cause of human genetic variation
and aﬀect the ability or eﬃciency of mRNA splicing. A major-
ity of the 5 0 splice site mutations involve the invariant ‘‘gt’’
dinucleotide at positions +1 or +2 of the intron. All can lead
to reduced or, as in our case, absent levels of mRNA from
the mutant allele, presumably involving the nonsense-mediated
mRNA decay pathway [14]. The data in Figs. 1 and 2 show a
major genetic eﬀect of the 5 0-intronic splice site mutation of the
P2X7 gene to produce a null allele in 1–2% of the Caucasian
population. The frequency of the P2X7 null allele in the Indian
population will require study of more subjects. However, our
data shows that the Indian and Caucasian variants arose
from separate mutational events on the 1513A and C alleles,
respectively.
The inheritance of a null allele has implications both for the
innate immune system as well as for inﬂammatory responses of
man. Thus, if the second allele contains another polymorphism
such as 1513C, 946A or 1729A, the function of the P2X7 locus
will be eﬀectively abolished with potential eﬀects on the ability
of cells of the monocyte–macrophage series to control obligate
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ations within this innate immune defense have focused on
polymorphisms within TOLL-like receptors, there is increasing
evidence that loss-of-function polymorphisms within the P2X7
gene are an alternative source of such variations. In humans,
homozygosity or double heterozygosity (compound heterozyg-
otes) of loss-of-function polymorphisms has been documented
to impair the ability of macrophages to achieve ATP-induced
killing of intracellular mycobacteria [4]. Moreover, ATP is un-
able to kill intracellular mycobacterium or Chlamydia tracho-
matis in macrophages obtained from P2X7 knockout mice
[5,15]. Activation of the P2X7 receptor is required for fusion
of lysosomes with the phagosomes of the macrophage and
the formation of a phagolysosome has been shown to be
dependent on phospholipase D (PLD) stimulation [3,15,16].
Moreover, Ca2+ dependent PLD activity is a well described
downstream eﬀect of P2X7 activation [17,18]. Inhibition of
the P2X7 receptor or its associated PLD activity will prevent
ATP-induced killing of engulfed pathogens by the macrophage
and may result in persistent intracellular infection.
Finally limited studies of the P2X7 knockout mouse show
attenuated joint inﬂammation in this murine model induced
by intra-articular injection of anti-collagen antibody [19].
The 1513C polymorphism in homozygous dosage is known
to impair ATP-induced release of pro-inﬂammatory cytokines,
interleukin-1b and interleukin-18, from human monocytes
[20,21] although clinical studies of P2X7 polymorphisms in hu-
man inﬂammatory diseases are lacking.
Acknowledgements: This work was supported by the National Health
and Medical Research Council, the Cure Cancer Australia Founda-
tion, the Leukemia Foundation of Australia and a Sesqui Fellowship
from the University of Sydney (B.J. Gu).References
[1] Gu, B.J., Zhang, W.Y., Bendall, L.J., Chessell, I.P., Buell, G.N.
and Wiley, J.S. (2000) Expression of P2X7 purinoceptors on
human lymphocytes and monocytes: evidence for nonfunctional
P2X7 receptors. Am. J. Phys. Cell Phys. 279, C1189–C1197.
[2] Lammas, D.A., Stober, C., Harvey, C.J., Kendrick, N., Panch-
alingam, S. and Kumararatne, D.S. (1997) ATP-induced killing of
mycobacteria by human macrophages is mediated by purinergic
P2Z(P2X7) receptors. Immunity 7, 433–444.
[3] Kusner, D.J. and Adams, J. (2000) ATP-induced killing of
virulent Mycobacterium tuberculosis within human macrophages
requires phospholipase D. J. Immunol. 164, 379–388.
[4] Saunders, B.M., Fernando, S.L., Sluyter, R., Britton, W.J. and
Wiley, J.S. (2003) A loss-of-function polymorphism in the human
P2X7 receptor abolishes ATP-mediated killing of mycobacteria. J.
Immunol. 171, 5442–5446.
[5] Coutinho-Silva, R., Stahl, L., Raymond, M.N., Jungas, T.,
Verbeke, P., Burnstock, G., Darville, T. and Ojcius, D.M.
(2003) Inhibition of chlamydial infectious activity due to
P2X7R-dependent phospholipase D activation. Immunity 19,
403–412.[6] North, R.A. (2002) Molecular physiology of P2X receptors.
Physiol. Rev. 82, 1013–1067.
[7] Surprenant, A., Rassendren, F., Kawashima, E., North, R.A. and
Buell, G. (1996) The cytolytic P2Z receptor for extracellular ATP
identiﬁed as a P2X receptor (P2X7). Science 272, 735–738.
[8] Wiley, J.S., Gargett, C.E., Zhang, W., Snook, M.B. and Jamie-
son, G.A. (1998) Partial agonists and antagonists reveal a second
permeability state of human lymphocyte P2Z/P2X7 channel. Am.
J. Phys. Cell Phys. 44, C1224–C1231.
[9] Wiley, J.S., Dao-Ung, L.P., Gu, B.J., Sluyter, R., Shemon, A.N.,
Li, C.P., Taper, J., Gallo, J. and Manoharan, A. (2002) A loss-of-
function polymorphic mutation in the cytolytic P2X7 receptor
gene and chronic lymphocytic leukaemia: a molecular study.
Lancet 359, 1114–1119.
[10] Gu, B.J., Sluyter, R., Skarratt, K.K., Shemon, A.N., Dao-Ung,
L.P., Fuller, S.J., Barden, J.A., Clarke, A.L., Petrou, S. and
Wiley, J.S. (2004) An Arg307 to Gln polymorphism within the
ATP-binding site causes loss of function of the human P2X7
receptor. J. Biol. Chem. 279, 31287–31295.
[11] Wiley, J.S., Dao-Ung, L.-P., Li, C., Shemon, A.N., Gu, B.J.,
Smart, M.L., Fuller, S.J., Barden, J.A., Petrou, S. and Sluyter, R.
(2003) An Ile-568 to Asn polymorphism prevents normal
traﬃcking and function of the human P2X7 receptor. J. Biol.
Chem. 278, 17108–17113.
[12] Gu, B.J., Zhang, W., Worthington, R.A., Sluyter, R., Dao-Ung,
P., Petrou, S., Barden, J.A. and Wiley, J.S. (2001) A Glu-496 to
Ala polymorphism leads to loss of function of the human P2X7
receptor. J. Biol. Chem. 276, 11135–11142.
[13] Dao-Ung, L.P., Fuller, S.J., Sluyter, R., Skarratt, K.K., Thun-
berg, U., Tobin, G., Byth, K., Ban, M., Rosenquist, R., Stewart,
G.J. and Wiley, J.S. (2004) Association of the 1513C polymor-
phism in the P2X7 gene with familial forms of chronic lympho-
cytic leukaemia. Br. J. Haematol. 125, 815–817.
[14] Maquat, L.E. (2004) Nonsense-mediated mRNA decay: splicing,
translation and mRNP dynamics. Nat. Rev. Mol. Cell Biol. 5, 89–
99.
[15] Fairbairn, I.P., Stober, C.B., Kumararatne, D.S. and Lammas,
D.A. (2001) ATP-mediated killing of intracellular mycobacteria
by macrophages is a P2X7-dependent process inducing bacterial
death by phagosome–lysosome fusion. J. Immunol. 167, 3300–
3307.
[16] Kusner, D.J. and Barton, J.A. (2001) ATP stimulates human
macrophages to kill intracellular virulent Mycobacterium tuber-
culosis via calcium-dependent phagosome–lysosome fusion. J.
Immunol. 167, 3308–3315.
[17] Gargett, C.E., Cornish, E.J. and Wiley, J.S. (1996) Phospholipase
D activation by P2Z-purinoceptor agonists in human lympho-
cytes is dependent on bivalent cation inﬂux. Biochem. J. 313, 529–
535.
[18] el-Moatassim, C. and Dubyak, G.R. (1992) A novel pathway for
the activation of phospholipase D by P2z purinergic receptors in
BAC1.2F5 macrophages. J. Biol. Chem. 267, 23664–23673.
[19] Labasi, J.M., Petrushova, N., Donovan, C., McCurdy, S., Lira,
P., Payette, M.M., Brissette, W., Wicks, J.R., Audoly, L. and
Gabel, C.A. (2002) Absence of the P2X7 receptor alters leukocyte
function and attenuates an inﬂammatory response. J. Immunol.
168, 6436–6445.
[20] Sluyter, R., Shemon, A.N. and Wiley, J.S. (2004) Glu496 to Ala
polymorphism in the P2X7 receptor impairs ATP-induced IL-1
beta release from human monocytes. J. Immunol. 172, 3399–3405.
[21] Sluyter, R., Dalitz, J.G. and Wiley, J.S. (2004) P2X7 receptor
polymorphism impairs extracellular adenosine 50-triphosphate-
induced interleukin-18 release from human monocytes. Genes
Immun. 5, 588–591.
